Bracco and Avicenna.AI have received U.S. Food and Drug Administration (FDA) 510(k) clearance for UPTUNITY | Aneurysm, an AI-enabled software solution designed to assist radiologists in detecting and monitoring brain aneurysms on computed tomography angiography (CTA) images. Announced on November 13, 2026, the clearance marks the first offering in Bracco’s new UPTUNITY portfolio and expands the imaging company’s digital health strategy into AI-assisted image interpretation. The software is designed to identify suspected saccular aneurysms larger than 3 mm and support quantitative comparisons across follow-up examinations.
Bracco and Avicenna.AI have received U.S. Food and Drug Administration (FDA) 510(k) clearance for UPTUNITY | Aneurysm, an AI-enabled software solution designed to assist radiologists in detecting and monitoring brain aneurysms on computed tomography angiography (CTA) images. Announced on November 13, 2026, the clearance marks the first offering in Bracco’s new UPTUNITY portfolio and expands the imaging company’s digital health strategy into AI-assisted image interpretation. The software is designed to identify suspected saccular aneurysms larger than 3 mm and support quantitative comparisons across follow-up examinations.
AI Moves Further Into Radiology Workflows
UPTUNITY | Aneurysm is intended to function as a concurrent reading aid for appropriately trained medical specialists reviewing head CTA scans. Its detection component flags images containing suspected aneurysms and provides information about their presence, location, and size.
The software focuses on saccular brain aneurysms larger than 3 mm. This is a defined scope, rather than a claim that the system detects every type or size of intracranial aneurysm. According to the FDA documentation for the underlying CINA-Aneurysm device, the software processes CTA images and provides localization overlays, vessel territory information, and maximum-diameter measurements to support clinical review.
The product also includes a follow-up capability marketed as UPTUNITY | Aneurysm Management. Based on the FDA-cleared CINA-Aneurysm+ software, this component provides quantitative measurements and comparisons between examinations. The aim is to help clinicians assess whether a known aneurysm has changed over time.
This longitudinal element is important because monitoring an unruptured aneurysm can involve repeated imaging. Consistent measurements may help specialists evaluate changes and inform decisions about subsequent clinical management.
Two FDA Clearances Underpin the Portfolio Launch
The UPTUNITY | Aneurysm commercial offering corresponds to two separately identified FDA 510(k) devices: CINA-Aneurysm, cleared under K262062, and CINA-Aneurysm+, cleared under K262147.
The FDA’s October 20, 2026 decision letter for CINA-Aneurysm states that the device was found substantially equivalent to legally marketed predicate devices for its stated indications for use. The FDA’s public record lists October 19, 2026 as the decision date for CINA-Aneurysm+.
The distinction matters. A 510(k) clearance is not the same regulatory pathway as premarket approval (PMA), and should not be described as FDA approval. It indicates that the FDA determined the device to be substantially equivalent to a legally marketed predicate device for its cleared intended use.
The cleared software is designed to support, not replace, physician interpretation. Its output must be considered alongside the original CTA images and the broader patient evaluation. The FDA documentation explicitly states that the software should not be used as a substitute for a full patient assessment or relied upon alone to make or confirm a diagnosis.
A Significant Clinical Need for Better Detection and Monitoring
Brain aneurysms can remain asymptomatic and may be discovered incidentally when patients undergo imaging for other reasons. The Brain Aneurysm Foundation estimates that approximately 6.8 million people in the United States have an unruptured brain aneurysm, equivalent to roughly one in 50 people.
That prevalence creates a continuing need for reliable imaging assessment and follow-up. However, the presence of an aneurysm does not mean it will rupture, and management decisions depend on clinical factors that extend beyond an imaging measurement.
CTA is one of the imaging techniques used to visualize cerebral blood vessels. Identifying small findings can be challenging, particularly when radiologists are reviewing large volumes of examinations. AI-assisted detection tools are being developed to highlight suspicious findings and provide additional measurements within established reading workflows.
Research published in The Lancet Digital Health in 2024 illustrates the potential of this approach. In a multicentre study of a different AI model for intracranial aneurysm detection, AI assistance improved clinicians’ diagnostic performance in a multi-reader evaluation and reduced average reading time. The findings support continued investigation of AI-assisted CTA interpretation, but they should not be treated as clinical performance evidence for UPTUNITY | Aneurysm itself.
Bracco Expands Beyond Contrast Agents
The launch also reflects Bracco’s broader move into digital health and interpretive AI. The company is known for diagnostic imaging products, including contrast agents, and is extending its portfolio toward software that helps clinicians interpret imaging data.
UPTUNITY complements AiMIFY, Bracco’s AI offering developed with Subtle Medical. AiMIFY applies AI to amplify existing contrast enhancement in brain MRI images, with the goal of improving lesion visualization. The newer UPTUNITY portfolio addresses a different part of the imaging workflow: identifying and assessing specific findings in medical images.
The collaboration with Avicenna.AI combines Bracco’s imaging-market presence with a software developer focused on AI applications for medical imaging. The companies announced a strategic partnership in March 2026 to advance AI applications in contrast-enhanced computed tomography.
Under the commercial arrangement announced for UPTUNITY | Aneurysm, Avicenna.AI will lead promotion and distribution in the United States. The companies are preparing for commercial introduction, although the announcement does not specify pricing, a detailed rollout timetable, or the initial number of healthcare facilities expected to adopt the software.
AI Medical Imaging Faces a Measurement Challenge
The market for radiology AI is moving from algorithms that flag potential abnormalities toward tools that support more structured assessment and longitudinal comparison. Detection is only one part of the clinical process. For conditions monitored over time, reproducible measurements and dependable comparisons between scans are also important.
That creates technical and clinical challenges. Differences in image quality, acquisition protocols, anatomy, and measurement methods can affect the interpretation of small changes. AI outputs therefore need to be evaluated in the context of their intended use and the evidence supporting each specific device.
For Bracco and Avicenna.AI, the next milestone will be translating regulatory clearance into clinical adoption. Integration into radiology workflows, interoperability with imaging systems, user training, and evidence from real-world use will all influence how the software performs in practice.
The companies plan to showcase UPTUNITY | Aneurysm at the Radiological Society of North America (RSNA) 2026 Annual Meeting in Chicago, scheduled for November 29 to December 3.
The launch gives Bracco a new position in AI-assisted radiology software and adds another entrant to a growing medical imaging AI market. Its longer-term significance will depend not simply on detecting suspicious findings, but on whether the technology can support consistent, clinically useful assessment while keeping physicians firmly in control of diagnosis and patient care.
Market Landscape
AI-assisted radiology is evolving from standalone image-flagging algorithms toward workflow-integrated tools that support detection, measurement, prioritization, and follow-up.
Brain aneurysm assessment is a particularly relevant application because some unruptured aneurysms are asymptomatic and discovered incidentally. The Brain Aneurysm Foundation estimates that around 6.8 million people in the United States have an unruptured brain aneurysm.
Top Insights
- Bracco and Avicenna.AI secured FDA 510(k) clearance for UPTUNITY | Aneurysm, the first product in Bracco’s new AI-enabled portfolio.
- The detection software targets suspected saccular brain aneurysms larger than 3 mm on head CTA images.
- A separate management capability supports quantitative measurements and comparisons across examinations for longitudinal aneurysm monitoring.
- FDA clearance establishes substantial equivalence for specified intended uses; it does not mean the software replaces physician review.
- Avicenna.AI will lead U.S. promotion and distribution as the companies prepare for commercial introduction.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
